The dietary supplement industry last week took another legislative knock to the chin as it was associated with controversy surrounding mislabled conventional foods, specifically Lazy Cakes, a brownie that contains the dietary ingredient melatonin and purports to be a dietary supplement.
Ten years ago the word probiotics wasn’t known, and five years ago it was a new word to most Americans. But thanks to the marketing of Activia yogurt by Dannon, which started in 2006, these microorganisms have garnered national attention.
The latest vindicator to the almost $3.5 billion vitamin and supplement business across all outlets isn’t positive press. It’s not even the continued consumer gravitation toward self-care. It’s Wall Street.
A new study indicated that two insulin products made by French drug maker Sanofi lower blood-glucose levels to a greater extent than premixed insulin, and with improvements in quality of life and less hypoglycemia.
An insulin product made by Eli Lilly appears likely to be more cost-effective than long-acting insulin analog, according to a study presented Friday at the American Diabetes Association’s 71st Scientific Sessions in San Diego.
A recent study published in Panminerva Medica found that a pycnogenol and coenzyme-Q10 combination (PycnoQ10) taken by stable heart failure patients as an adjunct to medical treatment naturally strengthens the heart, increasing the blood volume ejected with each beat.
Walgreens has teamed with Greater Than AIDS, a national campaign in response to HIV/AIDS in the United States, to distribute informational resources and specialized HIV-related services at more than 300 Walgreens pharmacies in heavily affected communities, the Kaiser Family Foundation announced Tuesday.
Elisa Technologies recently announced that its EZ Gluten test kit has earned Performance-Tested Methods certification from the AOAC Research Institute, a private, not-for-profit association that helps establish testing standards.
In the year leading up to the switch of Allegra, Sanofi generated $214.2 million in U.S. prescription sales of Allegra, largely due to the generic competition against its Allegra D formulation. Now Sanofi is looking to virtually match those annual sales figures within the much more profitable nonprescription venue with the company’s successful switch from prescription to OTC this spring.